How much is 90 mg of Stelara?

Learn more about this drug here. This is a brand name drug and a generic may be available. The average cost for 1 Syringe, 1ml of 90mg/ml each, is $29,754.71. You can buy Stelara at the discounted price of $20,582.16 by using the WebMDRx coupon, a savings of 31%.

Does Stelara go generic?

There are currently no generic alternatives to Stelara.

What is the cost of Stelara in Canada?

The annual cost of treatment with Stelara® is approximately $18,200 to $33,600, depending on whether the 45 mg or 90 mg dose is used. ClaimSecure clients will fully cover Stelara® under their existing open drug formularies.

How much is the first Stelara infusion?

Table 4Cost-Comparison Table of Biologics for the Treatment of Crohn’s Disease

Drug/Comparator	Strength	Price
Ustekinumab (Stelara)	90 mg/1.0 mL	$4,593.15a
Vedolizumab (Entyvio)	300 mg	$3,290.00d
Anti-TNF Alpha Therapies
Adalimumab (Humira)	40 mg	$769.97

Does Stelara lower your immune system?

This medication can affect your immune system. It can lower your body’s ability to fight an infection. You may be more likely to get serious infections, such as lung infections, bone/joint infections, skin infections, sinus infections, or bowel/gallbladder infections.

Can Stelara cause weight gain?

Can Stelara cause weight gain? No. Weight gain wasn’t reported as a side effect by people taking Stelara in clinical trials. However, people with Crohn’s disease, which Stelara is approved to treat, often experience weight loss.

What is the difference between Humira and Stelara?

Monoclonal antibodies mimic the effects of proteins made by your immune system. Stelara contains the monoclonal antibody ustekinumab. Ustekinumab belongs to a drug class* called interleukin-12 and interleukin-23 blockers. Humira contains the monoclonal antibody adalimumab.

How well does Stelara work for Crohn’s disease?

After 44 weeks, 53 percent of patients receiving Stelara injections every eight weeks were in remission. For patients getting Stelara every 12 weeks, 49 percent were in remission. This compared with 36 percent of those receiving a placebo, the researchers said.